Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

HIV/AIDS

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge
 

FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics

for Health Care Providers

FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics

The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.

It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is <=100,000 copies/mL, or as a substitute (switch) regimen for persons who are on a first ART regimen with sustained HIV suppression and no resistance mutations to the ARV components. Recommended dosage is 1 tablet once daily. As with Complera, it must be taken with a meal and cannot be taken concurrently with proton pump inhibitors.

FDA approval was not based on clinical studies showing efficacy of rilpivirine + emtricitabine + TAF but instead was based on pharmacokinetic (PK) studies showing similar plasma drug concentrations of TAF and emtricitabine as were seen with elvitegravir/cobicistat/emtricitabine/TAF, and bioequivalent levels of rilpivirine as with rilpivirine monotherapy. Efficacy and safety were inferred from other studies of the component ARVs.

Studies of TAF-containing regimens suggest that TAF may cause less risk of renal and bone toxicity than tenofovir disoproxil fumarate (TDF); further study will be needed to determine whether this is clinically relevant. For more information, see New Data on Tenofovir Alafenamide Fumarate. TAF is active against hepatitis B but has not been approved for treatment of hepatitis B.

Complera for Pediatric Patients

Meanwhile, the FDA announced that the coformulation rilpivirine + emtricitabine + TDF has been approved for pediatric patients age 13 to 18 years. Recommended dosage is the same as for adults, 1 tablet once daily with a meal.